Free tool
FAERS Monitor: Precedex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021038 or its brand name (Precedex, Dexmedetomidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,999
Serious
2,792
93% of reports
Hospitalization
1,116
Death reported
459
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bradycardia258
- off label use238
- hypotension181
- cardiac arrest172
- pyrexia116
- drug ineffective107
- product use in unapproved indication101
- pneumonia100
- product use issue92
- drug interaction86
- oxygen saturation decreased86
- respiratory failure86
- agitation82
- product administered to patient of inappropriate age79
- tachycardia74
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 10 |
| 2006 | 27 |
| 2007 | 21 |
| 2008 | 29 |
| 2009 | 34 |
| 2010 | 48 |
| 2011 | 59 |
| 2012 | 72 |
| 2013 | 86 |
| 2014 | 98 |
| 2015 | 104 |
| 2016 | 212 |
| 2017 | 188 |
| 2018 | 192 |
| 2019 | 238 |
| 2020 | 233 |
| 2021 | 207 |
| 2022 | 229 |
| 2023 | 270 |
| 2024 | 246 |
| 2025 | 258 |
| 2026 | 129 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,160 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administered to patient of inappropriate ageSignal | 79 | 92.3 | 74.1 | 6,952 |
| bradycardiaSignal | 258 | 34.3 | 30.5 | 8,285 |
| cardiac arrestSignal | 172 | 14.6 | 12.7 | 2,176 |
| oxygen saturation decreasedSignal | 86 | 10.7 | 8.7 | 751 |
| respiratory failureSignal | 86 | 8.3 | 6.7 | 544 |
| agitationSignal | 82 | 7.8 | 6.3 | 484 |
| hypotensionSignal | 181 | 6.3 | 5.5 | 815 |
| tachycardiaSignal | 74 | 5.8 | 4.7 | 293 |
| drug interactionSignal | 86 | 3.8 | 3.1 | 176 |
| product use issueSignal | 92 | 3.4 | 2.8 | 158 |
| product use in unapproved indicationSignal | 101 | 2.9 | 2.4 | 122 |
| pyrexiaSignal | 116 | 2.4 | 2.0 | 90 |
| pneumoniaSignal | 100 | 2.2 | 1.8 | 63 |
| off label use | 238 | 1.9 | 1.7 | 106 |
| drug ineffective | 107 | 0.6 | 0.5 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.